- Home
- ADUS vs HRMY Comparison
ADUS vs HRMY Comparison
Compare ADUS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- HRMY
- Stock Information
- Founded
- ADUS 1979
- HRMY 2017
- Country
- ADUS United States
- HRMY United States
- Employees
- ADUS 49703
- HRMY N/A
- Industry
- ADUS Medical/Nursing Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ADUS Health Care
- HRMY Health Care
- Exchange
- ADUS Nasdaq
- HRMY Nasdaq
- Market Cap
- ADUS 2.1B
- HRMY 2.0B
- IPO Year
- ADUS 2009
- HRMY 2020
- Fundamental
- Price
- ADUS $111.86
- HRMY $32.16
- Analyst Decision
- ADUS Buy
- HRMY Strong Buy
- Analyst Count
- ADUS 10
- HRMY 9
- Target Price
- ADUS $143.50
- HRMY $54.22
- AVG Volume (30 Days)
- ADUS 162.0K
- HRMY 620.8K
- Earning Date
- ADUS 08-04-2025
- HRMY 08-05-2025
- Dividend Yield
- ADUS N/A
- HRMY N/A
- EPS Growth
- ADUS 9.84
- HRMY 13.13
- EPS
- ADUS 4.42
- HRMY 2.62
- Revenue
- ADUS $1,211,561,000.00
- HRMY $744,852,000.00
- Revenue This Year
- ADUS $23.16
- HRMY $20.10
- Revenue Next Year
- ADUS $5.77
- HRMY $18.01
- P/E Ratio
- ADUS $25.33
- HRMY $12.27
- Revenue Growth
- ADUS 11.38
- HRMY 20.62
- 52 Week Low
- ADUS $88.96
- HRMY $26.47
- 52 Week High
- ADUS $136.72
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- ADUS 47.70
- HRMY 43.25
- Support Level
- ADUS $112.34
- HRMY $31.70
- Resistance Level
- ADUS $117.03
- HRMY $33.69
- Average True Range (ATR)
- ADUS 2.75
- HRMY 0.89
- MACD
- ADUS -0.59
- HRMY -0.10
- Stochastic Oscillator
- ADUS 26.46
- HRMY 37.30
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.